Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day
21 oct. 2021 08h30 HE
|
Silence Therapeutics plc
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day Announces plans to initiate a Phase 1 study in polycythaemia vera (PV) with SLN124, the third indication...